Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enphase Energy

Halliburton

W. R. Berkley

Despite the S&P 500 incurring a 15.7% YTD loss owing to inflation and high interest rates, stocks like ENPH, HAL, CAH and WRB have soared. They are poised to maintain the momentum in 2023.

4 S&P 500 Stocks Up More Than 30% YTD With More Room to Run

DUBLIN, Ohio , Dec. 9, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) released today its latest edition of Oncology Insights, a biannual, research-based report from Cardinal Health. Featuring perspectives from nearly 200 oncologists nationwide, the 12th edition of Oncology Insights focuses on patient diversity, health equity in oncology, care management and symptom monitoring.

New Cardinal Health research finds widespread acknowledgment of health inequities among oncologists

McKesson

Super Micro Computer

Outperforming the Zacks Oils and Energy sector in 2022 is no easy task. However, bulls have silently roamed in all three of these stocks, breaking the overall bearish trend we've become accustomed to.

3 Stocks Silently Outperforming Energy in 2022

AmerisourceBergen

Economic uncertainty hasn't been kind to Wall Street, but drug distributors — led by McKesson stock — have managed to weather the worst of the storm. The post McKesson Stock And Its Peers Carve Fat Gains From A Fearful Market appeared first on Investor's Business Daily.

McKesson Stock And Its Peers Carve Fat Gains From A Fearful Market

Cardinal Health, Inc. (NYSE:CAH ) Evercore ISI 5th Annual Healthcare Conference November 30, 2022 8:50 AM ET Company Participants Kevin Moran – Investor Relations Jason Hollar – Chief Executive Officer Conference Call Participants Elizabeth Anderson – Evercore ISI Kevin Moran Let's try this again. Good morning.

Cardinal Health, Inc. (CAH) Evercore ISI 5th Annual Healthcare Conference Transcript

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

Abbott Labs

Check out these three dividend aristocrats in the stock market this week.

Good Stocks To Invest In Now? 3 Dividend Aristocrats Stocks For Your List

Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.

Cardinal Health's (CAH) Velocare to Enhance at-Home Care

Launching as a pilot with Medically Home, new technology offering will reach patients in one to two hours  DUBLIN, Ohio , Nov. 15, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the launch of Velocare™, a supply chain network and last-mile fulfillment solution capable of reaching patients in one to two hours with critical products and services required for hospital-level care at home. Through a strategic collaboration with Medically Home, Cardinal Health at-Home Solutions is now supporting a Medically Home health system customer with Velocare, collectively enabling scaled, high-acuity care in the home.

Cardinal Health brings hospital-level care to the home with new supply chain solution

Transaction Data Systems Adds Cardinal Health's Outcomes Platform to Enable Greater Clinical Services

Cincinnati Financial

Cisco Systems

Diageo

Fulton Financial

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Paramount Global

Philip Morris

Schlumberger

TotalEnergies SE

Vanguard S&P 500 ETF

We received $801.63 in October dividend income. This was the first quarter we received a dividend from Vanguard's S&P 500 Index fund (VOO).

Bert's October Dividend Income Summary

Cardinal Health's (CAH) fiscal first-quarter results benefit from the solid performance of the Pharmaceutical segment.

Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates

Cardinal Health, Inc. (NYSE:CAH ) Q1 2023 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Kevin Moran - Vice President of Investor Relations Jason Hollar - Chief Executive Officer Trish English - Interim Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Lisa Gill - JPMorgan Kevin Caliendo - UBS Erin Wright - Morgan Stanley Michael Cherny - Bank of America Eric Percher - Nephron Research George Hill - Deutsche Bank A.J. Rice - Credit Suisse Charles Rhyee - Cowen Steven Valiquette - Barclays Operator Good day, and welcome to the First Quarter Fiscal Year 2023 Cardinal Health Earnings Conference Call.

Cardinal Health, Inc. (CAH) Q1 2023 Earnings Call Transcript

Cardinal (CAH) delivered earnings and revenue surprises of 25% and 5.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q1 Earnings and Revenues Surpass Estimates

Cardinal Health Inc. said its top line rose 13% in its recently completed quarter, with gains for its pharmaceutical business offsetting a decline in its medical segment.

Cardinal Health Quarterly Sales Up 13%

Cardinal Health topped first-quarter estimates on Friday and maintained its adjusted EPS view, leading CAH stock to rise. The post Cardinal Health Inches Higher On First-Quarter Beat, Maintained Guidance appeared first on Investor's Business Daily.

Cardinal Health Inches Higher On First-Quarter Beat, Maintained Guidance

Shares of Cardinal Health Inc. CAH, +0.83% jumped 4.4% toward a five-year high in premarket trading Friday, after the drug and laboratory products distributor reported fiscal first-quarter profit and revenue that beat expectations, as strength in generics and branded pharmaceuticals helped offset inflationary supply chain costs. Net income for the quarter to Sept.

Cardinal Health stock jumps toward 5-year high after big profit and revenue beats, affirmed outlook

Revenue increased 13% to $49.6 billion GAAP 1 operating earnings were $137 million, GAAP diluted EPS were $0.40 Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20 Company reaffirmed fiscal year 2023 non-GAAP EPS guidance DUBLIN, Ohio , Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 million in the Medical segment.

Cardinal Health Reports First Quarter Fiscal 2023 Results

DraftKings

The three major U.S. equity indexes closed lower on Tuesday. The Dow Jones industrials ended the day down 0.24%, the S&P 500 closed 0.41% lower and the Nasdaq retreated 0.89%.

Earnings Previews: Cardinal Health, DraftKings

Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for

Cheniere Energy

Steel Dynamics

Vertex Pharmaceuticals

S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market. The post S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength appeared first on Investor's Business Daily.

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength

American Airlines

Bunge Global SA

CVR Energy

Delta Air Lines

Broker-favorite stocks like American Airlines (AAL), Delta (DAL), CVR Energy (CVI), Bunge Limited (BG) and Cardinal Health (CAH) should be on an investor's watch list.

Check 5 Broker-Friendly Stocks for Returns Amid Market Chaos

Cardinal Health, which distributes branded and generic pharmaceuticals and other healthcare products, cleared a cup-with-handle buy point Wednesday.

Cardinal Health Clears Base, But Can It Maintain Uptrend?

DUBLIN, Ohio , Oct. 19, 2022 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its third edition of Rheumatology Insights , a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends impacting one of the fastest-growing areas of specialty medicine. The research revealed that rheumatologists are both more familiar with biosimilars and more comfortable prescribing them than they were in 2020, just in time for a wave of new biosimilars anticipated to hit the market in 2023.

News for Cardinal Health Stock (CAH)